News | May 30, 2025
Alkem reports 7.1% YoY revenue growth in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Annual EBITDA margin expands by 170 basis points
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Subscribe To Our Newsletter & Stay Updated
